BeiGene's (HKG:6160, SHA:688235) loss narrowed to $371.6 million in the first half from $729.6 million in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
Loss per share at the drug company halved to $0.27 from $0.54 a year earlier. Analysts polled by Visible Alpha expected a loss per share of $0.01.
Revenue grew to $1.68 billion from $1.04 billion the previous year. The Visible Alpha consensus forecast was $928.5 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。